Phase II randomized trail of Gemcitabine and Irinotecan in Patients with Platinum Refractory and Resistant Mullerian carcinoma (tailored dose vs optimal dose chemotherapy)

INTERVENTION: Patients were treated with irinotecan followed by gemcitabine on days 1 and 8 every 3 weeks. Irinotecan dose was fixed at 50 mg/ m2. In tailored dose chemotherapy arm gemcitabine dose was tailored to individualized maximum repeatable dose. In optimal dose chemotherapy arm gemcitabine dose was tailored to maximum tolerated dose. CONDITION: Patients with platinum refractory and resistant Mullerian carcinoma (ovarian cancer, fallopian tubal, primary peritoneal cancer) PRIMARY OUTCOME: Progression free survival SECONDARY OUTCOME: Adverse event ; Response Rate ( disease control rate) ; Overall Survival ; Tolerability ; Patient QOL INCLUSION CRITERIA: 1)Patients with a histological diagnosis of ovarian cancer (including fallopian tube, or primary peritoneal carcinoma) 2)Prior two regimens chemotherapy is required. Platinum‐resistant disease is based on the most recent exposure to a platinum‐based regimen and is defined as progressive disease within 6 months of completing the prior therapy. 3)Patients have at least one measurable disease. 4)No chemotherapy within 2 weeks prior to the registration 5)Patients who are 20 years old or older and younger than 79 years old at the enrollment 6)Performance status:ECOG 0‐2 7)Adequate bone marrow, renal, and hepatic function 8)Patients who are expected to survive more than 3 months. 9)Patients who have signed an approved informed consent.